#United States #Rockville #gene therapy #Rose Bio #David Enloe

Rose BioSolutions Welcomes David Enloe as CEO

Rockville, Maryland - September 8, 2026 - Rose BioSolutions, widely recognized in the biotech industry for its advanced manufacturing solutions and cellular materials for cell and gene therapy, proudly announces the appointment of David Enloe as the new Chief Executive Officer. This strategic addition comes at a time when the company seeks to leverage its unique positioning and fuel ongoing growth within the evolving biotechnology landscape.

David Enloe arrives with an impressive background, boasting over 35 years of leadership experience in the biotechnology and pharmaceutical sectors. His extensive career includes more than three decades focused on gene therapy and biopharmaceutical manufacturing. Throughout his journey, Enloe has played a pivotal role in the successful commercial launch of more than a dozen therapies, showcasing his ability to transform scientific innovations into market-ready solutions.

Enloe’s earlier career highlights include nearly 15 years at Introgen Therapeutics, where he contributed significantly to the company’s growth and success, eventually serving as President and CEO. He founded Vivante GMP Solutions, a specialized contract development and manufacturing organization (CDMO) for gene therapies centered around viral vector manufacturing. After this entity was acquired by Lonza, Enloe continued to lead the business, which became known as Lonza's Cell and Gene Therapy Business Unit.

His profound expertise extends to transforming and scaling CDMO operations. In his previous role as President and CEO at Societal CDMO, Enloe successfully repositioned the company, enhancing its operational, commercial, and organizational capabilities to fuel long-term growth. Similarly, during his tenure at Ajinomoto Bio-Pharma Services, he led the integration of four manufacturing organizations into a cohesive global CDMO, serving a diverse range of biotechnology and pharmaceutical clients.

The announcement drew positive remarks from industry insiders. Dave Kreter, Managing Director and Head of Healthcare Investments at GI Partners, noted: "David is a key figure who has helped shape the cell and gene therapy industry from its inception. His ability to foresee industry trends will be invaluable to us. We're excited to welcome him to Rose Bio, where he will harness our talented workforce and unique capabilities to accelerate growth in an expanding market."

For his part, Enloe expressed enthusiasm about his new role:

"Joining Rose Bio at such a critical juncture for both the company and the overall cell and gene therapy sector is incredibly exciting. My career has revolved around constructing businesses based on innovative science and aiding clients in delivering ground-breaking therapies to patients in need. The comprehensive spectrum of cellular materials, technical expertise, and established infrastructure at Rose Bio uniquely positions us to meet the evolving needs of our clients, positioning us as a key partner for the next phase of innovation and patient care in this industry."

Rose BioSolutions is recognized as a premier provider of development and advanced manufacturing capabilities within the realm of cell and gene therapy. Serving as a full-service CDMO, the company is designed to deliver customized solutions to its clients on timelines that lead the industry. Rose Bio specializes in manufacturing a full spectrum of plasmid DNA, viral vectors, and cell therapies while managing cell supply operations. With facilities situated in Rockville, Maryland, Memphis, Tennessee, Northridge, California, and Keele in the United Kingdom, Rose Bio is poised to push forward in the evolving landscape of biotechnology.

As they navigate a pivotal time for industry growth and innovation, Rose BioSolutions aims to capitalize on their partnership with David Enloe, ensuring they continue to provide high-quality services that clients rely upon, both now and as their needs evolve in the future.